A Phase II, Open Label Study of ZD6474 in Previously Treated Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC).
Phase of Trial: Phase II
Latest Information Update: 27 Mar 2015
At a glance
- Drugs Vandetanib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- Acronyms BATTLE
- 28 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Mar 2013 Planned end date changed from 1 Nov 2013 to 1 Nov 2014 as reported by ClinicalTrials.gov (NCT00410189).
- 11 May 2011 Planned end date changed from 1 Nov 2011 to 1 Nov 2012 as reported by ClinicalTrials.gov (NCT00410189).